THE
UVEOSCLERAL
PATH AWAITS


FINALLY, A SURGICAL PATHWAY
TO ENHANCE NATURAL OUTFLOW

THE MISSING MIDDLE:
WHY THIS TREATMENT
GAP EXISTS

Of the two primary natural outflow
pathways, only one has been effectively
harnessed surgically.
Trabecular Pathway
SLT / ALT
Canaloplasty
Goniotomy
Trabecular bypass stents
Uveoscleral pathway
No commercially available options—until now
Surgically under-
utilized natural
outflow system

THE EFFICACY
CLIFF: EVERY
SURGEON’S DILEMMA

When the efficacy of surgical trabecular interventions
plateaus, higher-risk bleb-forming procedures have
historically been the only remaining option.
Rx
  • Cholinergic (miotic)
  • Prostaglandin analog
  • Beta blocker
  • Carbonic anhydrase inhibitor
  • Adrenergic prodrug
  • Alpha-adrenergic agonist
Lasers
  • DSLT
  • SLT
  • ALT
MIGS
  • Canaloplasty
  • Goniotomy
  • Trabecular bypass stents
Tap to see what's missing
 
Bleb-forming
Procedures
  • Tubes
  • Trabeculectomy
  • Sub-conjunctival gel stents
Surgeons need more options
to fill this treatment gap
and further delay bleb-forming
procedures.

Nearly

1/3

of patients with glaucoma may be candidates for AlloFlotm Uveo1,2

How many are in your clinic?

Mild-to-moderate
open-angle
glaucoma
Mild-to-moderate open-angle glaucoma
  • 67-year-old, African American male
  • Pseudophakic—recently underwent cataract surgery with MIGS
  • Moderate uncontrolled glaucoma
  • Patient is on two medications and pressure is creeping back up
Post-MIGS with
waning efficacy
Post-MIGS with waning efficacy
  • 79-year-old, Hispanic female
  • Pseudophakic—had cataract surgery with concurrent MIGS 3 years ago
  • Patient is on three medications and has expressed a desire to reduce their medication burden
  • IOP is hovering above target
Experiencing
medication
intolerance
Experiencing medication intolerance
  • 83-year-old, Caucasian/white male
  • Pseudophakic—had cataract surgery with concurrent MIGS 6 years ago
  • Moderate progressive glaucoma
  • On multiple medications and non-compliant with drops, expressing medication intolerance
Risk concerns with
a bleb-forming
procedure
Risk concerns with a bleb-forming procedure
  • 63-year-old, Caucasian/white female
  • Phakic—high myopia with –7.00 D refraction
  • Diagnosed with ulcerative colitis, on long-term systemic immunosuppressant therapy
With millions2 of post-MIGS eyes nationwide, what if you could...
  • Delay the need for a
    bleb-forming procedure?
  • Surgically access a complementary, natural outflow path?
  • Add another surgical intervention to your toolkit?

Now, you can.

Introducing AlloFlotm UVEO dual bio-spacers

unlock natural
outflow through the
uveoscleral pathway

  • Bio-reinforcement of cleft to enhance uveoscleral outflow
  • Permeable structure facilitates aqueous conductivity
  • Work with your patients’ natural physiology—while you stay in the angle
Now you can access the complete physiologic outflow system of the eye.
Dimensions:
0.5 mm x 0.5 mm x 5 mm

Tailored for the eye,
From the eye

AlloFloTM Uveo tissue profile

  • Biological compatibility
    • Acellular; minimizes risk of immune response
    • Matches the native scleral structure
    • Reduces risk of fibrosis and foreign body reaction
  • Mechanical strength and durability
    • Robust structure resists deformation
    • Easy to manipulate and highly conforming
    • Non-biodegradable for long-term reinforcement
  • Facilitates aqueous conductivity
    • Naturally porous structure
AlloFloTM Uveo is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 and not as a drug, device, or biological product.

ALLOSERTTM UVEO CYCLODIALYSIS AND ALLOGRAFT
DELIVERY PLATFORM

Surgical precision + controlled
Bio-Reinforcement

  • Designed for creation of controlled cyclodialysis
  • Facilitates delivery and positioning of
    AlloFloTM Uveo
  • Choice of empty or pre-loaded carrier tips with hydrated AlloFloTM Uveo Dual Bio-spacers
  • Intuitive bio-tissue carrier assembly
  • Ergonomic, ambidextrous design
The only commercially-available surgical technology targeting uveoscleral outflow.
+

ALLOSERTTM UVEO HANDPIECE

Drag the handpiece to rotate in a 360-degree view.
Pinch to zoom.
Tap on Actuation Slider to activate.
Tap on the Reset Button to reset the actuator.
Tap on the Carrier to remove and install the tip.

Clinically Validated Bio-Interventional Approach

EVOLVING CYCLODIALYSIS FOR THE MINIMALLY-INVASIVE ERA

CYCLODIALYSIS
THE ABILITY FOR
CYCLODIALYSIS
TO SIGNIFICANTLY
REDUCE IOP
HAS BEEN
UNDERSTOOD FOR
OVER A CENTURY
Meta-analysis
of 40 evidence-
based studies3*:
  • More than 4,000 eyes
  • Data collected over a 100-year period
  • Up to 10 years of follow-up
  • Demonstrated average success rate comparable to MIGS
*Across all studies, the average qualified success rate was 72.3% (range: 33-97%) over follow-up periods of 6 to 132 months.
BIO-REINFORCED CYCLODIALYSIS
MINIMALLY INVASIVE WITH
IMPROVED PRECISION
& REPRODUCIBILITY OF
CYCLODIALYSIS CREATION
AND PATENCY

32-40%

MEAN IOP
REDUCTION4-7
12 & 24 months

40-64%

MEAN OHT
MEDICATION
REDUCTION4-7
12 & 24 months
EFFICACY PROFILE4-7
  • 1 & 2 year data
  • In combination: phaco or stand-alone
  • Diverse populations: Mild-to-severe glaucoma
SAFETY PROFILE
243 eyes Timeframe Percent of eyes
Clinical Hypotony5 ≥ 30 days < 0.5%
Elevated IOP**5 At/after 1 month
post-op		 < 5%
31 eyes Timeframe Mean ECL
Endothelial Cell Loss6 24 months < 10%†
** Procedure related, >30 mmHg or +10 mmHg from baseline
† Consistent with expected loss seen after cataract and microinvasive glaucoma surgery (MIGS) procedures. No eyes had significant (>30%) endothelial cell loss.
THE CREST STUDY:
ONE OF THE LARGEST PROSPECTIVE COHORTS IN INTERVENTIONAL GLAUCOMA

550+

eyes enrolled

175+

standalone cases

5

peer-reviewed puclications

2+

years

UNLOCK NATURAL OUTFLOW
THROUGH THE UVEOSCLERAL PATHWAY

“We are getting the most result for the least amount of surgery... least amount of disruption of the ocular anatomy.”
WATCH TESTIMONIAL:
Dr. James Lewis, MD
Elkins Park, PA
“What’s most exciting about AlloFlo [Uveo] really is that it’s a completely new pathway of treatment.”
WATCH TESTIMONIAL:
Dr. Arkadiy Yadgarov, MD
Atlanta, GA
“We’ve known for a long time that the uveoscleral pathway is the most prominent pathway that gets the pressure down. If we can get to it… then we win.”
WATCH TESTIMONIAL:
Dr. Michael Patterson, DO
Crossville, TN
AlloFlo and AlloSert are trademarks of Iantrek, Inc. ©2026 Iantrek, Inc. All rights reserved. PN 900222 Rev A
<
>